1. Home
  2. AKBA vs RM Comparison

AKBA vs RM Comparison

Compare AKBA & RM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • RM
  • Stock Information
  • Founded
  • AKBA 2007
  • RM 1987
  • Country
  • AKBA United States
  • RM United States
  • Employees
  • AKBA N/A
  • RM N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • RM Finance: Consumer Services
  • Sector
  • AKBA Health Care
  • RM Finance
  • Exchange
  • AKBA Nasdaq
  • RM Nasdaq
  • Market Cap
  • AKBA 336.2M
  • RM 291.2M
  • IPO Year
  • AKBA 2014
  • RM 2012
  • Fundamental
  • Price
  • AKBA $1.82
  • RM $29.69
  • Analyst Decision
  • AKBA Strong Buy
  • RM Hold
  • Analyst Count
  • AKBA 2
  • RM 3
  • Target Price
  • AKBA $5.75
  • RM $31.50
  • AVG Volume (30 Days)
  • AKBA 2.4M
  • RM 26.9K
  • Earning Date
  • AKBA 11-07-2024
  • RM 11-06-2024
  • Dividend Yield
  • AKBA N/A
  • RM 4.06%
  • EPS Growth
  • AKBA N/A
  • RM N/A
  • EPS
  • AKBA N/A
  • RM 2.41
  • Revenue
  • AKBA $169,879,000.00
  • RM $556,726,000.00
  • Revenue This Year
  • AKBA N/A
  • RM $13.14
  • Revenue Next Year
  • AKBA $6.13
  • RM $5.03
  • P/E Ratio
  • AKBA N/A
  • RM $12.44
  • Revenue Growth
  • AKBA N/A
  • RM 6.00
  • 52 Week Low
  • AKBA $0.80
  • RM $20.50
  • 52 Week High
  • AKBA $2.48
  • RM $34.15
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 56.59
  • RM 46.30
  • Support Level
  • AKBA $1.76
  • RM $28.94
  • Resistance Level
  • AKBA $2.02
  • RM $30.43
  • Average True Range (ATR)
  • AKBA 0.11
  • RM 1.18
  • MACD
  • AKBA -0.02
  • RM 0.01
  • Stochastic Oscillator
  • AKBA 40.00
  • RM 27.66

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About RM Regional Management Corp.

Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.

Share on Social Networks: